Apures Co (XKRX:149300) Change In Receivables : ₩41.4 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Apures Co Change In Receivables?

Apures Co's change in receivables for the quarter that ended in Dec. 2023 was ₩41.4 Mil. It means Apures Co's Accounts Receivable declined by ₩41.4 Mil from Dec. 2022 to Dec. 2023 .

Apures Co's change in receivables for the fiscal year that ended in Dec. 2023 was ₩41.4 Mil. It means Apures Co's Accounts Receivable declined by ₩41.4 Mil from Dec. 2022 to Dec. 2023 .

Apures Co's Accounts Receivable for the quarter that ended in Dec. 2023 was ₩25.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Apures Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 7.03.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Apures Co's liquidation value for the six months ended in Dec. 2023 was ₩-7,731.9 Mil.

Apures Co Change In Receivables Historical Data

The historical data trend for Apures Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Change In Receivables Chart

Apures Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-43.29

23.02

-165.81

117.12

41.41

Apures Co Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Change In Receivables	Get a 7-Day Free Trial					-43.29	23.02	-165.81	117.12	41.41

Apures Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 was ₩41.4 Mil.

Apures Co (XKRX:149300) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Apures Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	25.381	/	658.916	*	91
=	7.03

2. In Ben Graham's calculation of liquidation value, Apures Co's accounts receivable are only considered to be worth 75% of book value:

Apures Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	980.382	-	8910.89	+	0.75 * 25.381	+	0.5 * 359.114
=	-7,731.9

Apures Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Apures Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Apures Co (XKRX:149300) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792

Website

http://www.apures.com

Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines